CR-002 / Crescent Biopharma - LARVOL DELTA

Targeting PD-L1 Expressing Solid Tumors with CR-002, a Novel Topoisomerase 1-inhibitor (TOP1i) ADC Engineered for Increased Payload Delivery (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

ADC • Oncology • Solid Tumor

Recent Business Highlights & Anticipated Milestones: CR-002 (The Manila Times) - "Crescent is on track to submit an IND application to the U.S. Food and Drug Administration (FDA) for CR-002 in mid-2026 to support the initiation of a global Phase 1/2 trial in solid tumors in the second half of 2026, with proof-of-concept data expected in the second half of 2027."

IND • New P1/2 trial • P1/2 data • Solid Tumor

Crescent expects to submit an IND application for CR-002 in mid-2026 (The Manila Times)

IND • Oncology • Solid Tumor

Crescent Biopharma Strengthens Leadership Team with Appointment of Three Key Executives (PRNewswire) - "...'Our lead asset CR-001 remains on track for IND filing in the fourth quarter of this year, with first clinical data readout anticipated in the second half of 2026. Likewise, our novel ADCs CR-002 and CR-003 remain on track, with an IND for CR-002 expected in mid-2026. We continue to expect our reverse merger with GlycoMimetics to close in the second quarter of 2025, and the addition of these new leaders, along with the wealth of industry experience they bring, ensures we are well positioned to continue our momentum and capitalize on the rich set of opportunities before us'."

Commercial • IND • Solid Tumor